296P Clinical and molecular characteristics of NTRK fusion–positive solid tumors treated with entrectinib: An international multicenter retrospective real-world cohort study
ESMO Rare Cancers · 2026-03 · 5 · 100221
DOI: 10.1016/j.esmorc.2026.100221 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von J. Rodriguez Pascual und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pascual, J. R., Varga, L. U. D. L., Rodriguez-Castaño, J., Domingo, J. S., Silveira, S. D., Barrios, C. G., & Ayuso, A. (2026). 296P Clinical and molecular characteristics of NTRK fusion–positive solid tumors treated with entrectinib: An international multicenter retrospective real-world cohort study. ESMO Rare Cancers, 5, 100221. https://doi.org/10.1016/j.esmorc.2026.100221
Vancouver
Pascual JR, Varga LUDL, Rodriguez-Castaño J, Domingo JS, Silveira SD, Barrios CG, et al. 296P Clinical and molecular characteristics of NTRK fusion–positive solid tumors treated with entrectinib: An international multicenter retrospective real-world cohort study. ESMO Rare Cancers. 2026;5:100221. doi:10.1016/j.esmorc.2026.100221
BibTeX
@article{Pascual2026,
author = {Pascual, J. Rodriguez and Varga, L. Ugidos de La and Rodriguez-Castaño, J.D. and Domingo, J.J. Serrano and Silveira, S. Da and Barrios, C. Gimenez and Ayuso, A.},
title = {296P Clinical and molecular characteristics of NTRK fusion–positive solid tumors treated with entrectinib: An international multicenter retrospective real-world cohort study},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100221},
doi = {10.1016/j.esmorc.2026.100221}
}
EUVIMED